Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy

Summary

The purpose of this study is to evaluate the use of etanercept as a replacement therapy for ciclosporin in patients with plaque psoriasis.

Timeline

Start

2007-10

Primary completion

2009-11

Completion

2009-11

Outcome

Met primary endpoint

registry MEAN Placebo: 2.9 (1.0 to 4.8) scores on a scale MEAN Etanercept: -1.8 (-3.5 to -0.0) scores on a scale NCT00581555 ↗

registry analysis (superiority or other test); Placebo vs Etanercept; p <0.001; Mean Difference (Final Values) 4.7 (95% CI 2.1 to 7.3) NCT00581555 ↗

Publications

• Micali G, Wilsmann-Theis D, Mallbris L, Gallo G, Marino V, Brault Y, Germain JM. Etanercept reduces symptoms and severity of psoriasis after cessation of cyclosporine therapy: results of the SCORE study. Acta Derm Venereol. 2015 Jan;95(1):57-61. doi: 10.2340/00015555-1845.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etanercept	Protein / enzyme biologic	50 mg	Subcutaneous

Indications